Comparative genomic hybridization of ductal carcinoma in situ of the breast - Evidence of multiple genetic pathways

Journal of Pathology

Volumn 187, Issue 4, 1999, Pages 396-402

  Buerger, Horst ^c   Otterbach, Friedrich ^c   Simon, Ronald ^c   Poremba, Christopher ^c   Diallo, Raihanatou ^c   Decker, Thomas ^a   Riethdorf, Lutz ^c   Brinkschmidt, Christian ^c   Dockhorn Dworniczak, Barbara ^c   Boecker, Werner ^b  

^a Experimental Surgery and Regenerative Medicine   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c NONE

Author keywords

Breast cancer; CGH; In situ carcinoma

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER GENETICS; CANCER INVASION; CARCINOMA IN SITU; CHROMOSOME 11Q; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME DUPLICATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL DIFFERENTIATION; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NUCLEIC ACID HYBRIDIZATION;

EID: 0032980789     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L     Document Type: Article

References (48)

1. Bellamy COC, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast. The relevance of histologic categorization. Hum Pathol 1993; 24: 16-23.
2. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short term treatment failures. Cancer 1982; 50: 1309-1314.
3. Page DL, Lagios MD. Pathology and clinical evolution of ductal carcinoma in situ (DCIS) of the breast. Cancer Lett 1994; 86: 1-4.
4. Silverstein MJ, Lagios MD, Martino S, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998; 16: 1367-1373.
5. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 1997; 151: 161-168.
6. Tavassoli FA. Pathology of the Breast. Norwalk, CT: Appleton and Lange, 1992: 229-261.
7. Holland R, Peterse JL, Mills RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11: 167-180.
8. Lagios MD. Ductal carcinoma in situ: controversies in diagnosis, biology and treatment. Breast J 1995; 1: 68-78.
9. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol 1997; 28: 877-880.
10. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma in-situ. Lancet 1995; 345: 1154-1157.
11. Brinkschmidt C, Christiansen H, Terpe HJ, et al. Comparative genomic hybridization (CGH) analysis of neuroblastomas - an important methodological approach in paediatric tumour pathology. J Pathol 1997; 181: 394-400.
12. Kallioniemi AH, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-821.
13. Kallioniemi A, Kallioniemi OP, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 1994; 91: 2156-2160.
14. Ried T, Just KE, Holtzgreve-Grez H, et al. Comparative genomic hybridization of formalin-fixed, paraffin-embedded tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 1995; 55: 5415-5423.
15. Simon R, Bürger H, Brinkschmidt C, Böcker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with progression and invasion in superficial bladder cancer. J Pathol 1995; 185: 345-351.
16. Isola JJ, Kallioniemi OP, Chu LW, et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995; 147: 905-911.
17. European Commission. European Guidelines for Quality Assurance in Mammography Screening. Office for Official Publications of the European Communities, Brussels, 1996.
18. Ellis JO, Elston CW. Tumors of the breast. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. Edinburgh: Churchill Livingstone, 1995: 635-689.
19. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997; 75: 429-439.
20. Heim S, Mitelman F. Cancer Cytogenetics. New York: Wiley-Liss, 1995: 370-388.
21. Poremba C, Böcker W, Willenbring H, et al. Telomerase activity in human proliferative breast lesions. Int J Oncol 1998; 12: 641-648.
22. Stanta G, Bonin S, Losi L, Eusebi V. Molecular characterization of intraductal breast carcinomas. Virchows Arch 1998; 432: 107-111.
23. James LA, Mitchell ELD, Menasce L. Varley JM. Comparative genomic hybridization of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene 1997; 14: 1059-1065.
24. Kuukasjärvi T, Tanner M, Pennanen S, Karhu R, Kallioniemi OMP, Isola J. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol 1997; 150: 1465-1471.
25. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 1996; 56: 5605-5609.
26. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995; 48: 611-615.
27. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995; 175: 195-201.
28. Tsuda H, Callen DF, Fukutomi T, Nakamura Y, Hirohashi S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res 1994; 53: 513-517.
29. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. Genetic progression, histological grade and allelic loss in ductal carcinoma in situ of the breast Cancer Res 1996; 56: 5260-5265.
30. Radford DM, Fair KL, Philips NJ, et al. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p, 17q. Cancer Res 1995; 55: 3399-3405.
31. Tsuda H, Uei Y, Fukutomi T, Hirohashi S. Different incidence of loss of heterozygosity on chromosome 16q between intraductal papilloma and intracystic papillary carcinoma of the breast. Jpn J Cancer Res 1994; 85: 992-996.
32. Tsuda H, Fukutomi T, Hirohashi S. Pattern of gene alterations in intraductal breast neoplasms associated with historical type and grade. Clin Cancer Res 1995; 1: 261-267.
33. Cleton-Jansen AM, Moerland HW, Callen DF, Doggett NA, Devilee P, Cornelisse CJ. Mapping of the breast basic conseved gene (D16S444E) to human chromosome band 16q24.3. Cytogenet Cell Genet 1995; 68: 49-51.
34. Gupta SK, Douglas-Jones AG, Jasani B, Morgan JM, Pignatelli M. Mansel RE. E-cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch 1997; 430: 23-28.
35. Harrison MM, Magee HM, O'Loughlin JF, Gorey TF, Coyne JD, Dervan PA. Comparison of chromosome I aneusomy detected by interphase cytogenetics and DNA ploidy in carcinoma of the breast. Histopathology 1997; 30: 221-226.
36. Pandis N, Bardi G, Jin Y, et al. Unbalanced t(1:16) as the sole karyotypic abnormality in a breast carcinoma and its lymph node metastasis. Cancer Genet Cytogenet 1994; 75: 158-159.
37. Coene ED, Schelfhout V, Winkler RA, et al. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virchows Arch 1997; 430: 365-372.
38. De Potter CR, Foschini MP, Schelfhout A-M, Schroeter CA, Eusebi V. Immunohistochemical study of neu protein overexpression in clinging in situ duct carcinoma of the breast. Virchows Arch A [Pathol Anat] 1993; 422: 375-380.
39. Tsuda H, Iwaya K, Fukutomi T, Hiroshashi S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinoma of high histologic grade. Jpn J Cancer Res 1993; 84: 394-401.
40. Zafrani B, Leroyer A, Fourquet A. Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors. p53, and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994; 11: 208-214.
41. Radford DM, Fair K, Thompson AM, et al. Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 1995; 53: 2947-2950.
42. Peters G, Fantl V, Smith R, Brookes S, Dickson C. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treatment 1995; 33: 125-135.
43. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1995; 1: 1257-1260.
44. Sizinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 62: 621-630.
45. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-671.
46. Pagano M, Theodoras AM, Tam SW, Draetta GF. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994; 8: 1627-1639.
47. Chuaqui RF, Zhuang Z, Emmert-Buck MR, Liotta LA, Merino MJ. Analysis of loss of helerozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 1997; 150: 297-303.
48. Herbers J, Schullerus D, Muller H, et al. Significance of chromosome 14q losses in nonpapillary renal cell carcinomas. Genes Chromosomes Cancer 1997; 19: 29-35.